Rong Fan1, Yuefeng Zhang2, Yunqi Xu3, Jiayi Tong4, Zhigang Chen5, Meifeng Gu1, Wenkui Fan6, Yong Chen4, Fuhua Peng1, Ying Jiang1. 1. Department of Neurology and Multiple Sclerosis Research Center, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 2. Department of Neurology, Guangzhou Brain Hospital, Guangzhou, China. 3. Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China. 4. Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA. 5. Department of Neurology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China. 6. Department of Nephrology, The Second People's Hospital of Foshan, Foshan, China.
Abstract
BACKGROUND: Studies have demonstrated that antinuclear antibodies (ANAs) may be correlated with neuromyelitis optica spectrum disorder (NMOSD). However, the conflicting results of studies about the value of ANAs in AQP4 antibody-positive NMOSD patients need to be further investigated. MATERIAL: Case data were collected from 143 patients with AQP4 antibody-positive NMOSD. Patients were divided into two groups based on the ANA test results. The analysis of clinical characteristics, laboratory tests, and MRI examination results were compared between two groups: the NMOSD patients with ANA (+) and with ANA (-). RESULTS: Disease duration of NMOSD is shorter in the ANA (+) patients with EDSS < 4 than in the ANA (-) patients (12.05 ± 16.73 versus 29.43 ± 41.03, p-value = .013). The median time from disease onset to an EDSS score of 4.0 is significantly longer in the ANA (-) NMOSD patients than in the ANA (+) patients (48.2 months versus 24 months, p = .04). In addition, ANA (RR, 2.234; 95% CI, 1.078-4.629; p-value = .031) can predict the severity of NMOSD. CONCLUSIONS: Antinuclear antibodies seem to be associated with more severe disease activity in NMOSD patients.
BACKGROUND: Studies have demonstrated that antinuclear antibodies (ANAs) may be correlated with neuromyelitis optica spectrum disorder (NMOSD). However, the conflicting results of studies about the value of ANAs in AQP4 antibody-positive NMOSD patients need to be further investigated. MATERIAL: Case data were collected from 143 patients with AQP4 antibody-positive NMOSD. Patients were divided into two groups based on the ANA test results. The analysis of clinical characteristics, laboratory tests, and MRI examination results were compared between two groups: the NMOSD patients with ANA (+) and with ANA (-). RESULTS: Disease duration of NMOSD is shorter in the ANA (+) patients with EDSS < 4 than in the ANA (-) patients (12.05 ± 16.73 versus 29.43 ± 41.03, p-value = .013). The median time from disease onset to an EDSS score of 4.0 is significantly longer in the ANA (-) NMOSD patients than in the ANA (+) patients (48.2 months versus 24 months, p = .04). In addition, ANA (RR, 2.234; 95% CI, 1.078-4.629; p-value = .031) can predict the severity of NMOSD. CONCLUSIONS: Antinuclear antibodies seem to be associated with more severe disease activity in NMOSD patients.
Authors: María Laura Cerutti; Laura Mariana Zarebski; Gonzalo de Prat Gay; Fernando Alberto Goldbaum Journal: Mol Immunol Date: 2005-02 Impact factor: 4.407
Authors: Katharine E Harding; Mark Wardle; Robert Carruthers; Neil Robertson; Feng Zhu; Elaine Kingwell; Helen Tremlett Journal: Neurology Date: 2019-02-22 Impact factor: 9.910
Authors: Sean J Pittock; Vanda A Lennon; Jerome de Seze; Patrick Vermersch; Henry A Homburger; Dean M Wingerchuk; Claudia F Lucchinetti; Hélène Zéphir; Kevin Moder; Brian G Weinshenker Journal: Arch Neurol Date: 2008-01
Authors: Michael A Foster; Sara Collorone; Jacqueline Palace; James Acheson; Ahmed T Toosy Journal: Ann Clin Transl Neurol Date: 2021-06-24 Impact factor: 5.430